Download PDF
Thromb Haemost 1991; 65(02): 117-121
DOI: 10.1055/s-0038-1647467
Original Article
Schattauer GmbH Stuttgart

Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families

Bernhard Lämmle
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
,
Walter A Wuillemin
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
,
Isabelle Huber
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
,
Marina Krauskopf
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
,
Christian Zürcher
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
,
Rolf Pflugshaupt
*   Central Laboratory of the Swiss Red Cross, Bern, Switzerland
,
Miha Furlan
The Central Hematology Laboratory Inselspital, University of Bern, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Received: 28 June 1990

Accepted after revision 28 August 1990

Publication Date:
02 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In order to assess the clinical implications of hereditary F XII deficietrcy, all available members of Swiss families with F XII deficiency were investigated. Based on the F XII: C values and the family pedigree, the 74 subjects, aged 8-–82 years, were classified as homozygotes/double heterozygotes for F XII deficiency (n = 18), as obligatory (n = 20) or possibly (n = 25) heterozygotes, respectively, and as norrnals (n = 11). None of the 18 subjects with F XII: C <0.01 U/ml and only one possibly heterozygous woman had an abnormal bleeding tendency, confirming the notion that Hageman trait generally does not result in a hemorrhagic diathesis. Two of the 18 subjects with severe F XII deficiency had suffered from venous thromboembolic disease at age <40 years. One heterozygous woman had a leg ulcer probably due to venous thrombosis. Thus, whereas homozygous F XII deficiency may be associated with an increased risk for venous thromboembolic disease, partial F XII deficiency is not, by itself, a strong risk factor for thrombosis.

Where as 17 of the 18 subjects with F xII : C <0.01 U/ml had no detectable F XIL Ag, one cross reacting material-positive F XII deficient subject (F XII:Ag = 0.11 U/ml) was identified. The dysfunctional F XII, present in this subject's plasma and tentatively called F XII Bern, is the fourth abnormal F XII molecule identified so far.

 

  • References

  • 1 Ratnoff OD, Colopy JE. Familial hemorrhagic trait associated with deficiency of clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613
    CrossrefPubMedSearch in Google Scholar
  • 2 Ratnoff OD, Colopy JE. Biology and pathology of initial stages of blood coagulation. Progr Hematol 1966; 5: 204-245
    PubMedSearch in Google Scholar
  • 3 Griffin JH, Cochrane CG. Human factor XII (Hageman factor). Methods Enzymol 1976; 45: 56-65
    PubMedSearch in Google Scholar
  • 4 Fujikawa K, Davie EW. Human factor XII (Hageman factor). Methods Enzymol 1981; 80: 198-211
    PubMedSearch in Google Scholar
  • 5 Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Hemostas 1987; 13: 1-14
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci (USA) 1978; 75: 1998-2002
    CrossrefPubMedSearch in Google Scholar
  • 7 Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-1160
    PubMedSearch in Google Scholar
  • 8 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci (USA) 1976; 73: 2554-2558
    CrossrefPubMedSearch in Google Scholar
  • 9 Meier HL, Pierce JV, Colman RW, Kaplan AP. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest 1977; 60: 18-31
    PubMedSearch in Google Scholar
  • 10 Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241-306
    PubMedSearch in Google Scholar
  • 11 Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984; 73: 1249-1253
    PubMedSearch in Google Scholar
  • 12 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15
    PubMedSearch in Google Scholar
  • 13 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Ratnoff OD, Saito H. Surface mediated reactions. Curr Top Hematol 1979; 2: 1-57
    PubMedSearch in Google Scholar
  • 15 Saito H. Contact factors in health and disease. Semin Thromb Hemostas 1987; 13: 36-49
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Haanen C, Hommes F, Benraad H, Morselt G. A case of Hageman-factor deficiency and a method to purify the factor. Thromb Diath Haemorrh 1960; 5: 201-207
    PubMedSearch in Google Scholar
  • 17 Didisheim P. Hageman factor deficiency (Hageman trait). Arch Intern Med 1962; 110: 74-81
    PubMedSearch in Google Scholar
  • 18 Aznar J, Mayans J, Aznar JA, Fernandez-Pavon A, Calabuig R. Deficiencia de factor Hageman. A proposito de un caso. Sangre 1973; 18: 356-364
    PubMedSearch in Google Scholar
  • 19 Ikkala E, Myllyla G, Nevanlinna HR. Rare congenital coagulation factor defects in Finland. Scand J Haematol 1971; 8: 210-215
    PubMedSearch in Google Scholar
  • 20 Glueck HI, Roehill W. Myocardial infarction in a patient with a Hageman (factor XII) defect. Ann Intern Med 1966; 64: 390-396
    CrossrefPubMedSearch in Google Scholar
  • 21 Hoak JC, Swanson LW, Warner ED, Connor WE. Myocardial infarction associated with severe factor XII deficiency. Lancet 1966; 02: 884-886
    PubMedSearch in Google Scholar
  • 22 Ratnoff OD, Busse RJ, Sheon RP. The demise of John Hageman. N Engl J Med 1968; 279: 760-761
    CrossrefPubMedSearch in Google Scholar
  • 23 Baumann R, Straub PW. Congenital deficiency of Hageman factor (clotting factor XII). Report on the first two families found in Switzerland. Helv Med Acta 1968; 34: 313-326
    PubMedSearch in Google Scholar
  • 24 McPherson RA. Thromboembolism in Hageman trait. Am J Clin Pathol 1977; 68: 420-423
    CrossrefPubMedSearch in Google Scholar
  • 25 Dyerberg J, Stoffersen E. Recurrent thrombosis in a patient with fator XII deficiency. Acta Haematol 1980; 63: 278-282
    CrossrefPubMedSearch in Google Scholar
  • 26 Hellstern P, Kohler M, Schmengler K, Doenecke P, Wenzel E. Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency. Acta Haematol 1983; 69: 123-126
    CrossrefPubMedSearch in Google Scholar
  • 27 Lodi S, Isa L, Pollini E, Ferrari BravoA, Scalvini A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII deficiency and myocardial infarction. Scand J Haematol 1984; 33: 80-82
    PubMedSearch in Google Scholar
  • 28 Londino AV, Luparello FJ. Factor XII deficiency in a man with gout and angioimmunoblastic lymphadenopathy. Arch Intern Med 1984; 144: 1497-1498
    CrossrefPubMedSearch in Google Scholar
  • 29 Penny WJ, Colvin BT, Brooks N. Myocardial infarction with normal coronary arteries and factor XII deficiency. Br Heart J 1985; 53: 230-234
    CrossrefPubMedSearch in Google Scholar
  • 30 Vergnes C, Lorient-Roudaut MF, Haissaguerre M, Roudaut R, Wicker P, Boisseau MR, Dallocchio M. Thrombophlebites et embolies pulmonaires lors d’un deficit congenital en facteur XII. Arch Mai Coeur 1985; 78: 440-443
    PubMedSearch in Google Scholar
  • 31 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-255
    CrossrefPubMedSearch in Google Scholar
  • 32 Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-263
    PubMedSearch in Google Scholar
  • 33 Kluft C, Dooijewaard G. Faktor XII (Hageman-Faktor). Seine Rolle bei der Blutgerinnung und Fibrinolyse. Hamostaseologie 1988; 8: 102-109
    PubMedSearch in Google Scholar
  • 34 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: Greater in factor XII and XI than in factor VIII and IX deficiency. Blood 1984; 63: 1004-1014
    PubMedSearch in Google Scholar
  • 35 Thommen D, Sulzer I, Buhrfeind E, Naef R, Furlan M, Lammle B. Messung der Blutungszeit und Untersuchung der Thrombozy-tenaggregation. Standardisierung der Methoden, Normalwerte und Resultate bei Patienten mit Verdacht auf hamorrhagische Diathese. Schweiz Med Wschr 1988; 118: 1559-1567
    PubMedSearch in Google Scholar
  • 36 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-254
    CrossrefPubMedSearch in Google Scholar
  • 37 Lammle B, Berrettini M, Griffin JH. Enhanced specificity of immunoblotting using radiolabeled antigen overlay. Studies of blood coagulation factor XII and prekallikrein in plasma. Anal Biochem 1986; 156: 118-125
    PubMedSearch in Google Scholar
  • 38 Thommen D, Buhrfeind E, Felix R, Sulzer I, Furlan M, Lammle B. Hamostaseparameter bei 55 Patienten mit venosen und/oder arteriel-len Thromboembolien. Schweiz Med Wschr 1989; 119: 493-499
    PubMedSearch in Google Scholar
  • 39 Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1983; 21: 709-720
    PubMedSearch in Google Scholar
  • 40 Aznar J, Fernandez PavonA. Thromboembolic accidents in patients with congenital deficiency of factor XII. Thromb Diath Haemorrh 1974; 31: 525-526
    PubMedSearch in Google Scholar
  • 41 Saito H, Scott JG, Movat HZ, Scialla SJ. Molecular heterogeneity of Hageman trait (factor XII deficiency). Evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Clin Med 1979; 94: 256-265
    PubMedSearch in Google Scholar
  • 42 Berrettini M, Lammle B, Ciavarella G, Ciavarella N. Functional and immunological studies of abnormal factor XII in a cross reacting material positive (CRM+) factor XII deficiency. Thromb Haemostas 1985; 54: 120 (Abstract).
    PubMedSearch in Google Scholar
  • 43 Saito H, Scialla SJ. Isolation and properties of an abnormal Hageman factor (factor XII) molecule in a cross-reacting material-positive Hageman trait plasma. J Clin Invest 1981; 68: 1028-1035
    CrossrefPubMedSearch in Google Scholar
  • 44 Miyata T, Kawabata SI, Iwanaga S, Takahashi I, Alving B, Saito H. Coagulation factor XII (Hageman factor) Washington D. C.: Inactive factor XIIa results from Cys-571 Ser substitution. Proc Natl Acad Sci (USA) 1989; 86: 8319-8322
    PubMedSearch in Google Scholar